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SUMMARY
Despite correlations between histone methyltrans-
ferase (HMT) activity and gene regulation, direct
evidence that HMT activity is responsible for gene
activation is sparse. We address the role of the HMT
activity for MLL1, a histone H3 lysine 4 (H3K4)
methyltransferase critical formaintaining hematopoi-
etic stem cells (HSCs). Here, we show that the SET
domain, and thus HMT activity of MLL1, is dispens-
able for maintaining HSCs and supporting leukemo-
genesis driven by the MLL-AF9 fusion oncoprotein.
Upon Mll1 deletion, histone H4 lysine 16 (H4K16)
acetylation is selectively depleted at MLL1 target
genes in conjunction with reduced transcription. Sur-
prisingly, inhibition of SIRT1 is sufficient to prevent
the loss of H4K16 acetylation and the reduction in
MLL1 target gene expression. Thus, recruited MOF
activity, and not the intrinsic HMT activity of MLL1,
is central for the maintenance of HSC target genes.
In addition, this work reveals a role for SIRT1 in
opposing MLL1 function.
INTRODUCTION
Understanding the contribution of chromatin-modifying com-
plexes to precise and heritable patterns of gene regulation in
mammals has been a challenging task due to the complexity,
redundancy, and, often, ubiquitous expression of such com-
plexes. Among the first factors shown to influence the heritable
transmission of gene expression states were trithorax Group
(trxG) and Polycomb group (PcG) proteins (Cavalli and Paro,
1999; Schuettengruber et al., 2011). Following their genetic iden-
tification in Drosophila melanogaster, a common protein domain
defined by Su(var)3-9, Ezh2, Trithorax (SET) homology was sub-
sequently demonstrated to possess histone methylation activity.
More recently, it has become clear that histone methylation en-
zymes beyond the trxG/PcG homologs function in many aspects
of epigenetic gene regulation from yeast to human (Shilatifard,
2012).
The first identified mammalian member of the trxG family,
MLL1, was initially noted as a gene frequently rearranged
in poor-prognosis leukemia (Grossmann et al., 2012; Krivtsov
and Armstrong, 2007). Mammals possess three pairs of related
SET-domain containing histone methyltransferase (HMT) pro-
teins, MLL1/2, SET1A/B, MLL3/4, and a divergent MLL5 protein.
In addition to MLL1 translocations in leukemia, mutations in
several trxG/MLL family members are associated with develop-
mental disorders and cancer (Jones et al., 2012; Morin et al.,
2011; Ng et al., 2010; Parsons et al., 2011; Pasqualucci et al.,
2011). How these broadly expressed proteins influence partic-
ular physiologic and pathologic processes in specific cell types
is largely unknown but, due to their enzymatic activities, repre-
sent attractive drug targets.
Tissue-specific loss-of-functionmodels togetherwithbiochem-
ical approaches have delineated biologically important target
genes and candidate mechanisms by which mammalian trxG/
MLL family proteins function. The fact that these large proteins
function within multiprotein complexes and frequently lack satis-
factory in vivo structure-function assays has limited our under-
standing of gene regulatory mechanisms used in the tissues in
which they function. To determine MLL1 function in vivo, we em-
ployed inducible Mll1 loss-of-function alleles and demonstrated
thatMll1plays a unique and essential role inHSCsanddeveloping
Bcells (Artingeret al., 2013; Judeetal., 2007;Li et al., 2013). These
studies also revealed MLL1 target genes that were MLL1 depen-
dent only in hematopoietic cells, presumably due to tissue-spe-
cific mechanisms of recruitment (Artinger et al., 2013).
The native MLL1 complex purified from cell lines revealed
several stoichiometric components, particularly a C-terminal
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subcomplex that is critical for HMT activity and specificity (Dou
et al., 2005, 2006; Nakamura et al., 2002; Patel et al., 2011; Stew-
ard et al., 2006; Yokoyama et al., 2004). Detailed mechanistic
studies show that the MLL1 SET domain, in conjunction with
the Wdr5/RbBP5/Ash2L/Dumpy-30 (WRAD) subcomplex, acts
as a H3K4 mono- and dimethylation, or in some conditions, a tri-
methylation enzyme (Dou et al., 2006; Patel et al., 2011; Steward
et al., 2006). Given the connection between H3K4me1 and active
enhancer regions as well as H3K4me3 and active/poised tran-
scriptional start sites (reviewed in Maunakea et al., 2010), inves-
tigators have naturally hypothesized that MLL1 family HMTs
regulate transcription via promoter or enhancer targeted H3K4
methylation.
To determine the mechanisms by which MLL1 maintains
expression of its target genes in hematopoietic cells, we investi-
gated the requirement for HMT activity using domain-specific
deletion and conditional knockout mouse models. Surprisingly,
we found that the SET domain of MLL1 was not necessary for
maintaining the expression of direct target genes in hematopoi-
etic populations, or for facilitating MLL-AF9-mediated leukemo-
genesis. Through acute deletion of Mll1, we identified a histone
H4 modification that was rapidly and synchronously reduced
as the expression of MLL1 target genes ceased. This modifica-
tion implicates the MLL1-associated MOF histone acetyltrans-
ferase as the dominant activity maintaining transcription of
MLL1 target genes. Remarkably, pharmacologic inhibition of
H4K16Ac deacetylases was sufficient to restore MLL1-depen-
dent gene expression in Mll1D/D cells. Collectively, our data
implicate MLL1-recruited H4K16Ac activity, and not HMT activ-
ity, as the major mechanism by which gene expression is main-
tained in hematopoietic stem and progenitor cells (HSPCs).
Furthermore, our data implicate Sirtuins as opposing factors in
the transcriptional network maintained by MLL1 in HSPCs.
RESULTS
Hematopoiesis in the Absence of the MLL1 SET Domain
All MLL family members harbor a SET domain with specificity for
H3K4 methylation, dependent upon associated cofactors or
posttranslational modifications (Patel et al., 2014; Schuetten-
gruber et al., 2011). Most Mll1 disruption alleles are embryonic
lethal; however, homozygotes for a germline deletion of the
SET domain of MLL1 (hereafter, DSET) survive into adulthood,
providing an opportunity to assess the role of the SET domain,
thus HMT activity of MLL1, in adult tissues (Terranova et al.,
2006). Homozygous DSET mutants were generated, and west-
ern blotting of thymocyte extracts confirmed the expression of
the predicted size MLL1 C-terminal band (Figure S1A). Mature
lymphoid and myeloid populations in the bone marrow and
blood of DSET animals were present at normal frequencies
(P.E., data not shown). Because HSPCs are extremely sensitive
to loss of Mll1 (Gan et al., 2010; Jude et al., 2007; McMahon
et al., 2007), we carefully assessed the phenotype and function
of HSPCs in DSET mutant mice.
Steady-state HSPCs from wild-type (WT), heterozygotes
(DSET/+), and homozygousDSETmicewere quantified by deter-
mining the total lineage-negative (linneg), Sca-1-positive, c-Kit-
positive (LSK) cells in animals of several age ranges (Figures
1A–1C). Given that there were no significant differences in
this population, we examined the more HSC-enriched LSK/
CD150+/CD48neg population and found the number of these
cells was indistinguishable between WT and DSET animals
(Figures 1D and 1E). For functional quantification of HSCs, we
performed competitive repopulation unit (CRU) assays using
unfractionated bone marrow cells. Consistent with the pheno-
typic data, WT and DSET bone marrow exhibited overlapping
CRU frequencies (Figure 1F). To identify potentially subtle gene
expression defects in DSET cells, we performed real-time quan-
titative PCR (qPCR) analyses using sorted LSK cells. We found
that the strongly MLL1-dependent target genes Hoxa9, Mecom
(locus encoding MDS-Evi1 and Evi1 transcripts), and Prdm16
(Artinger et al., 2013) were expressed at normal levels in DSET
cells (Figure 1G). Similarly, H3K4me3 and H3K4me1 enrichment
around the transcription start site (TSS) of these loci was also un-
changed in DSET HSPCs (Figure S1B). These surprising findings
suggested that the MLL1 HMT activity is dispensable for regu-
lating target genes and therefore HSPC function. To assess po-
tential compensation by members of the WRAD subcomplex
(Cao et al., 2010; Patel et al., 2011) or other HMTs, we knocked
down components of HMT complexes inWT andDSET inmurine
embryo fibroblasts (MEFs) and linneg bone marrow cells. Deple-
tion of Ash2L had no effect on Hoxa9 expression in either WT or
DSET MEFs, whereas depletion of Wdr5 reduced expression of
Hoxa9 equivalently in both genotypes (Figures S1C and S1D).
Because Wdr5 is also required for SET1A/B HMT complexes
(Lee and Skalnik, 2008), we knocked down Wdr82, a subunit
uniquely required for SET1A/B complex function (Lee and
Skalnik, 2008; Austenaa et al., 2012). Depletion of Wdr82
reduced Hoxa9 expression slightly in both WT and DSET MEFs
(Figure S1E). Similar trends were observed with the hematopoi-
etic-specific (Artinger et al., 2013) target gene Mecom in linneg
bonemarrow cells (Figures S1F andS1G), although less effective
knockdown in this cell type reduced the statistical significance.
Thus, DSET cells do not exhibit an increased dependence
on potential compensatory HMTs or C-terminal subcomplex
components.
MLL-AF9 Transforms DSET Cells
Several lines of evidence suggested that endogenous MLL1 is
required for transformation by MLL1 fusion oncoproteins (Milne
et al., 2010; Thiel et al., 2010). For example, in Mll1/ MEFs
MLL-AF9 cannot localize to the Hoxa9 gene, but reintroduction
of a human MLL1 cDNA restored Hoxa9 promoter localization
(Milne et al., 2010). To test whether histone methylation by
endogenous MLL1 is required for MLL-AF9-mediated transfor-
mation, we initiated leukemia in both WT and DSET HSPCs
and followed quantitative and qualitative features of the resulting
acute myelogenous leukemia (AML). As shown in Figure 2A, the
latency of MLL-AF9 initiated AML in the DSET background
was indistinguishable from that initiated in WT cells. Leukemia
initiated from either WT or DSET cells was characterized by
similar high white blood cell (WBC) counts, percentages of
Gr-1 ± /Mac-1+ cells, suppression of erythropoiesis, and spleno-
megaly (Figures 2B–2E). Qualitatively, animals receiving either
WT or DSET MLL-AF9-transformed cells exhibited similar
histopathology (Figure S2A) and comparable levels of Hoxa9
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expression and histone modifications at the Hoxa9 promoter,
including the H3K79Me2 modification recruited by the AF9
fusion partner (Figures S2B–S2E). Furthermore, secondary
transplantation of leukemia cells (Figure 2F) and serial replating
assays (Figure 2G) demonstrated that leukemia-initiating capac-
ity and self-renewal are not affected by the loss of endogenous
MLL1 HMT activity. In summary, none of the known hematopoi-
etic functions ofMLL1 appear to require theHMT activity or pres-
ence of the SET domain generally.
Acute Deletion of MLL1 Has No Impact on H3K4
Methylation in HSPCs
To identify changes in chromatin that are directly influenced
by the MLL1 complex, we established a system to temporally
resolve gene downregulation and chromatin modifications
in primitive hematopoietic cells. Using 4-hydroxytamoxifen
(4-OHT) inducible cre recombinase (ERT2-cre) animals in which
ex vivo deletion ofMll1 resulted in rapid target gene downregula-
tion (Artinger et al., 2013), we determined transcript levels and
chromatinmodifications over a period of 3 days, duringwhich lin-
neg bone marrow cells remain phenotypically undifferentiated
(B.P.M., data not shown). ERT2-cre;Mll1F/+ cells were used as
controls because target gene expression is indistinguishable
Figure 1. Normal HSCNumber, Function, and
Gene Expression in DSET Animals
(A–C) LSK cells were quantified from littermates of
3–4 weeks (A), 5–9 weeks (B), or 6–8 months old (C)
n = 3–7 animals for each genotype. The cell number
on the y axis reflects total number per two hin-
dlimbs.
(D) Representative fluorescence-activated cell
sorting plots of LSK-gated cells.
(E) Total LSK/CD150+/CD48neg cells per two hin-
dlimbs, n = 5–6 animals per genotype at 4–6 weeks
of age.
(F) CRU quantification for bone marrow from WT or
DSET animals, n = 3–7 recipients and three donors
per cell dose. Inset table shows mean CRU ± range,
determined using L-Calc software.
(G) Expression of MLL1 target genes in WT or DSET
LSK cells. LSK cells were sorted from the bone
marrow of 6- to 12-week-old animals, n = 5–6 per
genotype. Error bars reflect mean gene expression
level per donor animal ±95% confidence interval.
between WT and heterozygous cells (Fig-
ures S3A and S3B) and induction of cre
recombinase can affect cell viability and
gene expression. Within 36 hr of Mll1
deletion, the levels of Hoxa9, Mecom, and
Prdm16 transcripts were reduced (Fig-
ure 3A). An assessment of H3K4 methyl-
ation enrichment at these target genes
by chromatin immunoprecipitation (ChIP)-
qPCR demonstrated the stability of these
histone modifications during the time
course despite complete excision of Mll1
(Figures 3B–3E and S3C–S3F). Therefore,
despite dramatic changes in gene expression, acute MLL1 loss
does not result in H3K4 methylation differences at its target
gene promoters.
To test whether these observations were generalizable
in a more HSC-enriched population, we performed ChIP-
sequencing (ChIP-seq) with sorted LSK cells from control
ERT2-cre;Mll1F/+ or ERT2-cre;Mll1F/F animals. In this system,
48 hr was sufficient to reduce MLL1 target gene expression (Fig-
ures S4A and S4B). We examined Hoxa9, Evi1, and Prdm16 TSS
regions and found a remarkable consistency in H3K4me3 and
H3K4me1 enrichment comparing control and Mll1D/D samples
(Figure 4A), which was true genome-wide at all enriched loci
(Figures 4B and 4C). Despite the downregulation of over 300
genes (Artinger et al., 2013), the changes in H3K4me enrichment
vary only within the range observed between replicate samples
(Figures S4C and S4D). These data demonstrate that the HMT
activity of MLL1 is not responsible for the maintenance of target
gene expression in HSPCs.
H4K16 Acetylation at MLL1 Targets Is Lost in Parallel
with Transcription
To identify chromatin changes that occur uponMll1 deletion, we
surveyed histone modifications at MLL1 target gene promoters
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throughout the time course shown in Figure 3. MLL1 interacts
physically and/or genetically with p300/CBP, MOF, and MOZ
histone acetyltransferases (Dou et al., 2005; Ernst et al., 2001;
Paggetti et al., 2010). Although the CBP/p300-mediated
H3K27Ac and MOZ-mediated H3K9Ac modifications were
stable throughout the time course (Figures S4E, S5A, and
S5B), H4K16Ac was rapidly reduced around the TSS of MLL1
target genes in Mll1D/D cells (Figure 5A) as was MOF itself (Fig-
ure 5B). Polycomb-complex-mediated H3K27me3 modifica-
tions increased, but late in the time course, suggesting they
occur as a secondary consequence of cessation of transcription
(Figures S5E and S5F). Interestingly, DSETmutant linneg cells ex-
hibited unchanged H4K16Ac enrichment, whether gene-specific
or global levels were assessed (Figures S5G and S5H).
Because MOF-mediated acetylation creates a binding site for
Brd4, which recruits the PTEFb transcriptional elongation com-
plex (Yang et al., 2005; Zippo et al., 2009), we assessed pro-
moter Brd4 and Cdk9 levels (the latter representative of the
PTEFb complex). As shown in Figures 5C and 5D, Brd4 and
Cdk9 were also reduced at MLL1 target genes. Consistent with
the reduced Cdk9, the actively elongating form of RNA polymer-
ase II (serine 2 phosphorylated) was also decreased (Figure 5E).
These data suggest that MLL1 loss results in the rapid loss
of promoter H4K16Ac, and, as a consequence, reduced Brd4
Figure 2. MLL-AF9 AML Is Initiated and
Propagated Normally inDSET Hematopoietic
Cells
(A) Kaplan-Meier plot of primary leukemia in re-
cipients transplantedwithMLL-AF9-transducedWT
or DSET bone marrow cells, n = 9 per genotype.
(B) Phenotypic analysis of leukemia cells from tis-
sues of moribund animals. Cells from the indicated
organs were stained with Mac-1 and Gr-1 anti-
bodies and YFP+-gated cells shown.
(C and D) Automated differential counts were
determined using peripheral blood cells from
leukemic animals (n = 9 per genotype) and age-
matched controls (n = 2). White blood cells (WBCs,
C) and red blood cells (RBC, D) are shown from the
18 animals represented in (A).
(E) Spleen weight of leukemic animals when mori-
bund and control animals as in (C) and (D).
(F) Secondary transplantation results using 100
(solid lines) or 1,000 (dashed lines) YFP+ leukemia
cells, n = 4 recipients per genotype.
(G) MLL-AF9-transformed cells exhibit similar serial
replating activity in vitro. Leukemia cells from pri-
mary recipients were plated in methylcellulose me-
dium and colonies quantified and replated every
week, corresponding to the replating number below
the pairs of bars.
Data represent means of triplicate reactions ±SD.
and PTEFb recruitment. In addition, both
serine 5 phosphorylated, paused RNA po-
lymerase II (ser5 Pol II, Figure 5F) and
nascent Hoxa9, Evi1 (specific isoform
from the Mecom locus), and Prdm16 tran-
scripts were reduced upon Mll1 deletion,
demonstrating a role for MLL1 in enhancing transcriptional initi-
ation (Figures S5C and S5D). These data show that the MLL1
complex maintains target gene expression through both tran-
scriptional initiation and elongation, in part, through maintaining
H4K16Ac levels by recruitment of MOF.
Role of Sirtuin Family Deacetylases in Opposing MLL1-
Dependent Gene Expression
If MLL1-associated MOF is required for maintaining MLL1 target
genes in HSPCs, we predicted that blocking H4K16 deacetyla-
tion might enhance the expression of MLL1 target genes. Both
SIRT1 and SIRT2 deacetylate H4K16Ac, the former acting
constitutively in the nucleus and the latter cytoplasmic enzyme
acting mainly on chromatin at the G2/M transition (Martı´nez-Re-
dondo and Vaquero, 2013). To test the role of these enzymes in
MLL1-dependent gene expression, we used the class III histone
deacetlylase inhibitor nicotinamide or the SIRT1-specific inhibi-
tor Ex-527 (Napper et al., 2005) in conjunction withMll1 deletion.
Remarkably, either inhibitor could restore MLL1 target gene
expression in Mll1D/D cells (Figure 6). Interestingly, treatment
with Ex-527 had a negligible effect on MLL1 target gene expres-
sion in WT cells, although induction of Cdkn1 was observed
(Figures S6A and S6B). Induction Cdkn1 occurs through deace-
tylation and thereby activation of the nonhistone SIRT1 target
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p53 (Yuan et al., 2013). Ex-527 treatment did not affect the effi-
ciency of Mll1 deletion (Figure S6D) but did restore H4K16Ac
levels of MLL1 target genes without having an impact on
H3K4me3 levels (Figures S6E and S6F). These data demonstrate
that the role of MLL1 in maintaining hematopoietic-specific
target genes occurs largely through associated MOF acetylation
activity, which continuously counters the potential repressive ac-
tions of SIRT1.
DISCUSSION
We show that MLL1 maintains the expression of its hematopoi-
etic target genes using mechanisms that do not depend on its
HMT activity or other molecules that interact with the SET
domain. Despite the fact that DSET homozygous animals
exhibit transient Hox gene misexpression and altered H3K4me
enrichment during embryogenesis (Terranova et al., 2006),
these perturbations are apparently not sufficient to cause em-
bryonic lethality or overt phenotypes in adult animals. Careful
analysis of the hematopoietic system in DSET animals revealed
normal cellular homeostasis, engraftment, support of MLL-AF9
leukemogenesis, gene expression, and target gene histone
modifications in HSPCs. In contrast, acute deletion of Mll1 in
HSPCs had a dramatic impact on gene expression but was
also not accompanied by reduced H3K4me at MLL1 target
genes. Rather, the coordinate reduction in MOF-mediated
H4K16Ac and MLL1 target gene expression suggested a major
role for this associated acetyltransferase in maintaining MLL1
target genes in HSPCs. The correlation between MLL1 function
and H3K4me3 promoter modification may be the indirect result
of the gene maintenance activity, such that active transcrip-
tion results in H3K4me3 modifications through the action of
the more broadly active SET1A/B complexes. This hypothesis
is supported by our finding that DSET and WT cells are equiva-
lently sensitive to depletion of Wdr5, Ash2L, and Wdr82,
all required for SET1A/B activity (Figures S1C–S1G). In the
case of acute deletion of Mll1, we propose that failure to
recruit MOF to MLL1 target genes results in the rapid loss of
H4K16Ac enrichment through opposing SIRT1 action, making
the genes susceptible to Polycomb-mediated repression and
ultimately the reduction in H3K4me3 levels. Our observations
do not rule out that H3K4me3 modification at MLL1 target
genes is involved in the heritability of expression state but
illustrate particularly in the case of the DSET mutant that these
modifications are likely performed by a distinct enzyme and not
MLL1 itself.
Although the SET domain/enzymatic activity of several MLL-
related proteins have been shown to be critical for gene regula-
tion (Ding et al., 2012; Lee et al., 2006; Tie et al., 2014), recent
evidence suggests that MLL1 and MLL2 exhibit very specialized
H3K4me activities that are restricted to particular cell types and
target genes (Andreu-Vieyra et al., 2010; Austenaa et al., 2012;
Glaser et al., 2009; Ladopoulos et al., 2013). Nonetheless,
both MLL1 and MLL2 regulate many unique gene expression
Figure 3. Loss of MLL1 in Hematopoietic Cells Does Not Affect H3K4me Enrichment at Target Genes
(A) Transcripts corresponding to three representative MLL1 target genes decrease rapidly upon 4-OHT-induced excision ofMll1 in vitro. Linneg cells were purified
from control ERT2-cre;Mll1F/+ or ERT2-cre;Mll1F/F bonemarrow andwere cultured in vitro inmedium containing 400 nM 4-OHT. Triplicate samples were harvested
every 12 hr for real-time qPCR (A) and ChIP (C–E) assays.
(B) Diagram of target gene loci showing ChIP amplicon location, approximately 1 kb to either side of the TSS (see Table S1).
(C–E) Anti-H3K4me1, -H3K4me2, and -H3K4me3 ChIP assays were performed using samples from the 48 hr time point. Enrichment of the indicated histone
modification is shown for each amplicon as the mean of four PCRs ±SEM. ChIP results are representative of at least three independent experiments.
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programs above and beyond genes that are directly H3K4-meth-
ylated. Interestingly, an HMT-inactive mutant of the Arabidopsis
Trx ortholog, Atx1, retained its ability to recruit preinitiation com-
ponents to the promoters of its target genes, but exhibited
reduced RNA Pol II elongation (Ding et al., 2012), demonstrating
that non-HMT functions of Atx1 can play significant and sepa-
rable roles in transcriptional maintenance. Our data reinforce
the concept that HMTs, particularly MLL family members, affect
target gene expression through mechanisms other than their
HMT activity.
MOF interacts with the C-terminal portion of MLL1 (Dou et al.,
2005). Because this region is not retained in most MLL1 fusion
oncoproteins, this interaction is not predicted to play a role in
leukemogenesis, where the de novo recruitment of PTEFb or
DOT1 complexes by the fusion partner may override the need
for MOF activity. Given these qualitative differences in how
fusion proteins and endogenous MLL1 regulate genes, selective
targeting of the oncoprotein may be more feasible than originally
imagined.
The involvement of Sirtuins in opposing trxG function and
working in parallel with PcG proteins has been previously noted.
In Drosophila, Sir2 homozygous mutations enhance E(Z) and
other homeotic PcG phenotypes, although Sir2 mutations alone
do not cause homeotic phenotypes. These authors also showed
a physical association between SIR2 and E(Z) in larval extracts
and on chromatin (Furuyama et al., 2004). The observation that
genes with trithorax binding sites are among those selectively
activated by the MOF/NSL complex further suggests that a
trx-MOF-Sir2-PcG pathway may be broadly used in develop-
ment (Feller et al., 2012) such that the sequential actions of
H4K16 deacetylation then PcG repression terminate transient
developmental gene expression. The biochemical activity of
trx required to confer heritability of expression state to target
genes remains unclear, but interestingly, early studies using
the Fab-7 trx/PcG response element implicated histone H4
acetylation as the epigenetic mark leading to the heritable
maintenance of Fab-7 linked reporter genes (Cavalli and Paro,
1999). Thus, the MOF-Sirtuin balance may play a role in such
epigenetic decisions.
Recent work (Cao et al., 2014) concluded that the HMT activity
of MLL1 is required to support MLL-AF9-mediated leukemogen-
esis. The authors demonstrated that the MLL1 HMT activity
depends on WDR5 interaction and that a novel pharmacologic
inhibitor of this interaction both reduces MLL-AF9 colony growth
and affects gene expression in a manner similar to the condi-
tional deletion of endogenous Mll1 in the MLL-AF9-transformed
cells. Significant differences in approaches used between our
two studies may underlie the distinct conclusions. For example,
in vivo effects of the pharmacologic inhibitor may result from
mechanisms other than the MLL1 HMT inhibition demonstrated
in vitro. In addition, the distinct hypomorphic Mll1 conditional
allele used exhibits milder phenotypes than that used in our
study. Future studies using HMT inhibitors and DSET/MLL-AF9
cells may clarify this discrepancy.
Figure 4. Genome-wide Comparison of H3K4me1 and H3K4me3 Enrichment in Purified Mll1D/D HSPCs
(A) Representative ChIP-seq tracks showing reads per million (y axis). LSK cells were sorted from control ERT2-cre;Mll1F/+ or ERT2-cre;Mll1F/F animals and
cultured in vitro in HSC medium 48 hr (300 nM 4-OHT for only the first 24 hr). Complete deletion of Mll1 was confirmed (Figure S4B). The locus is diagrammed
below the tracks.
(B and C) Scatterplots showing the concordance between enriched regions in a representative pair of control versus Mll1D/D samples. Each dot represents
enrichment of the indicated histonemodification within a bin of 1 kb. Differentially enriched bins in controlMll1D/+ LSK cells are shown in green and those enriched
in Mll1D/D LSK cells are shown in red. Pairwise comparisons between different replicate pairs yielded similar results and concordance between replicates is
shown in Figures S4C–S4E.
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EXPERIMENTAL PROCEDURES
Flow Cytometry and Cell Sorting
Linneg bone marrow cells were prepared using a custom rat antibody mix and
Dynal goat anti-rat magnetic beads, routinely yielding cells that are 80%
lineage negative/low; flow cytometry and cell sorting were performed as
described (Artinger et al., 2013).
Animals, Cell Culture, and In Vitro Induction of cre Recombinase
Animal studies were performed in accordance with the Dartmouth Institutional
Animal Care and Use Committee. DSET animals (Terranova et al., 2006) and
Mll1F/F animals (Jude et al., 2007) were backcrossed to the B6.SJL strain using
the Dartmouse speed congenic facility. MEFs were prepared using standard
methods from day 14 embryos. For ChIP-qPCR and ChIP-seq studies, Mll1
was deleted in vitro from either lineage-depleted bone marrow or sorted
LSK cells from two to six pooled ERT2-cre;Mll1F/+ or ERT2-cre;Mll1F/F animals
as detailed in the Supplemental Information.
RNA Preparation and Real-Time qPCR
Total RNA was extracted with Trizol (Life Technologies) and purified with
RNeasy kits (QIAGEN). For real-time qPCRs, 0.5 mg RNA was used to synthe-
size cDNA using Superscript III (Life Technologies), and analyses were per-
formed on a 7500 fast real-time PCR system (Applied Biosystems) using
primers or TaqMan assays in the Supplemental Information; relative expres-
sion was normalized to Gapdh.
Retroviruses and Leukemia Analyses
The MLL-AF9-IRES-YFP MSCV plasmid was from Dr. Armstrong (MSKCC).
Retroviral supernatants were prepared by cotransfection as described
(Artinger et al., 2013). MLL-AF9-transduced cells were mixed with 4 3 105
C57Bl/6 bone marrow cells and injected into lethally irradiated recipients,
and animals were sacrificedwhenmoribund. YFP+ splenocytes frommoribund
animals were injected into lethally irradiated secondary recipients. Peripheral
blood and organ analyses are detailed in the Supplemental Information. Small
hairpin RNA (shRNA) plasmids were from Drs. Vakoc (Cold Spring Harbor
Laboratories) or Natoli (IFOM-IEO, Milan). Replating experiments were per-
formed by culturing fresh leukemia cells in methylcellulose plus cytokines
(M3434, STEMCELL Technologies), counting colonies, and replating every
6–7 days.
ChIP-qPCR and ChIP-Seq
A miniChIP protocol (Attema et al., 2007) was used with antibodies detailed
in the Supplemental Information. ChIP-seq libraries were prepared following
the manufacturer’s suggestions (Ovation Ultralow Library Systems, NuGEN).
Figure 5. MOF-Mediated H4K16 Acetylation Parallels MLL1 Target Gene Expression
ChIP assays performed 48 hr after initiatingMll1 deletion as in Figure 3A. Nuclei from linneg cells were fixed and ChIP performed using anti-H4K16Ac (A), -MOF
(B), -Brd4 (C), -Cdk9 (D), -phospho-ser2 Pol II (E), and phospho-ser5 Pol II (F). Amplicons are as diagrammed in Figure 3B. Data represent mean of two to four
replicates ±SEM and are representative of at least three experiments. ND, not determined.
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Multiplexed sequencing was performed on a HiSeq2000 instrument (Illumina).
Details are provided in the Supplemental Information.
SIRT1 Inhibitor Studies
Linneg cells from ERT2-cre;Mll1F/+ or ERT2-cre;Mll1F/F animals were cultured in
medium supplemented with 400 nM 4-OHT dissolved in ethanol and Ex-527
(Sigma) or Nicotinamide (Sigma) were dissolved in DMSO. One million cells
werecollected inTrizolorfixedasdescribedaboveandstoredat80Cuntil use.
Statistics
CRU data were calculated with L-Calc (STEMCELL Technologies). Statistics
and graphing were performed with Excel (Microsoft) or Prism (GraphPad).
Error bars reflect mean ± SEM unless otherwise indicated in the legends. Sig-
nificance for Kaplan-Meier curves was calculated using the log-rank test.
ACCESSION NUMBERS
The GEO accession number for the ChIP-seq data reported in this paper is
GSE56456.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.04.015.
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